Life expectancy

Worldwide Shape Memory Materials Industry to 2026 - North America to Dominate the Market - ResearchAndMarkets.com

Thursday, October 21, 2021 - 4:47pm

The medical industry across the globe is increasing at a significant rate owing to the technological advancements and preference towards quality based medical treatment.

Key Points: 
  • The medical industry across the globe is increasing at a significant rate owing to the technological advancements and preference towards quality based medical treatment.
  • Hence, owing to these factors, the healthcare industry is likely to witness the highest market share during the forecast period.
  • Additionally, the demand for shape memory polymers from the aerospace sector exhibited significant growth in the near past.
  • Hence, owing to the above-mentioned factors, North America is likely to dominate the market studied during the forecast period.

Less Talk, More Action: New Report Sponsored by ViiV Healthcare Provides Roadmap to Achieve Health Equity by 2040

Wednesday, October 20, 2021 - 2:13pm

Healthcare disparities are defined as avoidable and unfair differences in the health of people or particular groups that negatively impact their quality of life and life expectancy.

Key Points: 
  • Healthcare disparities are defined as avoidable and unfair differences in the health of people or particular groups that negatively impact their quality of life and life expectancy.
  • This report provides a roadmap for that action, so that we can move forward from discussing disparities to implementing real change that will improve health equity.
  • A shared, forward-looking vision that shows us what achieving health equity looks like is critical to success.
  • The full detailed findings of Achieving health equity: a roadmap to eliminating disparities , as well as additional resources related to the report can be found at viivhealthcare.com .

MiSalud Launches Spanish-Language Digital Health App for Underserved Hispanic Communities in California

Tuesday, October 19, 2021 - 7:05pm

MiSalud confronts health inequities within the Hispanic community via the launch of their Spanish-language digital health platform, now available in the Google Play Store.

Key Points: 
  • MiSalud confronts health inequities within the Hispanic community via the launch of their Spanish-language digital health platform, now available in the Google Play Store.
  • Easy access to a digital health platform in Spanish is a game changer for the Hispanic community.
  • MiSaluds digital health solution puts Spanish-speaking healthcare in the hands of the growing Hispanic community in California, who typically only visit a doctor for urgent or emergency health needs.
  • With a culturally authentic approach to health and wellness, MiSalud is equipped to address both preventative health and immediate health concerns.

Generac Unveils New MLTB Light Tower

Monday, October 18, 2021 - 3:00pm

WAUKESHA, Wis., Oct. 18, 2021 /PRNewswire/ --Generac Mobile, a leading manufacturer of mobile light towers, generators, heaters, pumps and dust suppression solutions, today announced the introduction of the new MLTB, an innovative battery light tower that is the first of its kind to be offered by Generac.

Key Points: 
  • WAUKESHA, Wis., Oct. 18, 2021 /PRNewswire/ --Generac Mobile, a leading manufacturer of mobile light towers, generators, heaters, pumps and dust suppression solutions, today announced the introduction of the new MLTB, an innovative battery light tower that is the first of its kind to be offered by Generac.
  • The MLTB is the industry's first high-intensity, DOT-certified light tower driven by Generac's Green Lithium Battery technology.
  • The MLTB can be used individually or linked with additional Generac plug-in towers, allowing for increased flexibility and versatility in lighting events and jobsites.
  • The new unit is equipped with four 240W high-performance, Generac G4 LED fixtures that provide maximum light.

ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)

Monday, October 18, 2021 - 11:34am

ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders , conducted by Michl A.A.P.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders , conducted by Michl A.A.P.
  • The study investigated ChromaDexs proprietary Niagen ingredient (patented nicotinamide riboside, or NR) in patients with ataxia-telangiectasia (AT), a rare, inherited neurodegenerative disorder characterized by premature aging, cerebellar degeneration, immunodeficiency, and cancer predisposition.
  • The study found that supplementation with NR improved ataxia scores and increased immunoglobulins, or antibodies, in the immune-compromised patients.
  • The results of this study are promising for those living with AT and are consistent with previous preclinical research.

Lirio Launches Precision Nudging™ Solution to Improve Colorectal Cancer (CRC) Screening Adherence

Thursday, October 14, 2021 - 1:46pm

KNOXVILLE and NASHVILLE, Tenn., Oct. 14, 2021 /PRNewswire/ --Lirio,whose Precision Nudging solution promotes health throughAI-poweredbehavior change, today announced the launch of a new Precision Nudging solution to encouragepeople to schedule and attend colorectal cancer screenings with theirhealthcare providers.

Key Points: 
  • KNOXVILLE and NASHVILLE, Tenn., Oct. 14, 2021 /PRNewswire/ --Lirio,whose Precision Nudging solution promotes health throughAI-poweredbehavior change, today announced the launch of a new Precision Nudging solution to encouragepeople to schedule and attend colorectal cancer screenings with theirhealthcare providers.
  • Rochester Regional Health (RRH)in New York is the first health system to deploy the solution for its patient population.
  • According to the American Cancer Society (ACS), colorectal canceris the third leading cause of cancer-related deathsamongAmericanmen and women.
  • ACS recommends colorectal cancer (CRC) screenings every 10 years for people aged 45-75 who have average risk levels.

Vitality International - Pioneering Algorithm Calculates The Number Of Years Individuals Can Expect To Live In Good Health

Tuesday, October 12, 2021 - 3:40pm

LONDON, Oct. 12, 2021 /PRNewswire/ -- Vitality today reveals research results quantifying the widening gap between lifespan (life expectancy) and healthspan (the number of years lived in good health) globally, reflecting a diminishing quality of life in later years. Alongside this research, Vitality and RAND Europe have developed a pioneering algorithm that allows individuals, for the first time, to understand how their lifestyle choices impact both their length and quality of life, enabling them to take actions to maximise the number of years spent in good health in the future.

Key Points: 
  • Alongside this research, Vitality and RAND Europe have developed a pioneering algorithm that allows individuals, for the first time, to understand how their lifestyle choices impact both their length and quality of life, enabling them to take actions to maximise the number of years spent in good health in the future.
  • The research and algorithm were launched at Vitality's global conference with keynote speakers Professor Yuval Noah Harari and Discovery / Global Vitality CEO, Adrian Gore, to debate solutions for improving the future health of individuals and populations.
  • This outcome follows health strategies that prioritise treatment over prevention, and technologiesthat enable people to live longer with disease.
  • Currently, the world spends $8.5 trillion or 10% of GDP on healthcare delivery with only 5% going towards prevention.

Vitality International - Pioneering Algorithm Calculates The Number Of Years Individuals Can Expect To Live In Good Health

Tuesday, October 12, 2021 - 3:10pm

Alongside this research, Vitality and RAND Europe have developed a pioneering algorithm that allows individuals, for the first time, to understand how their lifestyle choices impact both their length and quality of life, enabling them to take actions to maximise the number of years spent in good health in the future.

Key Points: 
  • Alongside this research, Vitality and RAND Europe have developed a pioneering algorithm that allows individuals, for the first time, to understand how their lifestyle choices impact both their length and quality of life, enabling them to take actions to maximise the number of years spent in good health in the future.
  • The research and algorithm were launched at Vitality's global conference with keynote speakers Professor Yuval Noah Harari and Discovery / Global Vitality CEO, Adrian Gore, to debate solutions for improving the future health of individuals and populations.
  • This outcome follows health strategies that prioritise treatment over prevention, and technologiesthat enable people to live longer with disease.
  • Currently, the world spends $8.5 trillion or 10% of GDP on healthcare delivery with only 5% going towards prevention.

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing

Tuesday, October 12, 2021 - 12:30pm

There were no drug-related severe or serious adverse events at doses up to and including 120 mg/kg single dose and 80mg/kg multi-dose.

Key Points: 
  • There were no drug-related severe or serious adverse events at doses up to and including 120 mg/kg single dose and 80mg/kg multi-dose.
  • Drug-related adverse events were predominantly mild with a few moderate events and all were transient and reversible.
  • Alpha-1 antitrypsin deficiency, or AATD, is an inherited orphan disease affecting an estimated 100,000 patients in the United States.
  • This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

Inhibrx To Host Webcast Presentation of Interim Results from the Phase 1 Trial of INBRX-101, its Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

Monday, October 11, 2021 - 9:05pm

Following the webcast, the presentation may be accessed through a link on the "Investors" section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations .

Key Points: 
  • Following the webcast, the presentation may be accessed through a link on the "Investors" section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations .
  • Following the presentation, Inhibrx will update its corporate presentation within the "Investors" section of its website at www.inhibrx.com .
  • Alpha-1 antitrypsin deficiency, or AATD, is an inherited orphan disease affecting an estimated 100,000 patients in the United States.
  • Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.